Sidewinder Therapeutics
Last verified 2026-06-17. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $200.0Mattributed |
|---|---|
| Latest round | series-b, $137.0M, 2026-04-01attributed |
| Founded | 2021 |
| Headquarters | San Diego, US |
| Industry | bio |
| Stage | series-b+ |
| Website | sidewinder-tx.com |
Sidewinder Therapeutics is a San Diego clinical-stage biotech developing precision bispecific antibody-drug conjugates for hard-to-treat solid tumors. It targets squamous-cell carcinomas of lung and head/neck and gastrointestinal cancers. The ADCs bind receptor co-complexes on tumor cells; a $137M Series B takes the lead to clinic in 2027.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-04-01 | series-b | $137.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $137.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $200.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | sidewinder-tx.com, read 2026-06-17 |
| Description | self-reported | sidewinder-tx.com, read 2026-06-17 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.